Prokarium to attend LSX Conference in London, May 10-11

Kristen Albright, Prokarium’s CEO, will be presenting on May 11 at 2.30pm at the LSX Conference in London

Related News

Prokarium Announces Upcoming Oral Presentations of Interim Clinical Data at the EAU and AUA 2026 Annual Meetings

London, UK – 16 February 2026 – Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment...

Prokarium appoints Ibs Mahmood as Chief Executive Officer

London, UK – November 11, 2025 – Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

Prokarium appoints Ibs Mahmood as Chief Executive Officer

London, UK – November 11, 2025 – Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer

LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...

Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer

LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...